People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evofem Biosciences, Inc. | — | Biotechnology | Series B | $133.6M | $4.3M | 2019 |
Gillian Greer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gillian Greer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Lynch | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| William Hall | 1 | 5 |
| Jenny Yip | 1 | 3 |
| Thomas F. Darden II | 1 | 3 |
| Simon Best | 1 | 2 |
| Kim P. Kamdar | 1 | 2 |
| Natalie Douglas | 1 | 2 |
| Alexander A. Fitzpatrick | 1 | 2 |
| Kelly F. Culwell | 1 | 1 |
| Natalie F. Douglas | 1 | 1 |
| Jay F. File | 1 | 1 |
| John F. Fair | 1 | 1 |
| Colin F. Rutherford | 1 | 1 |
| Ellen F. Thomas | 1 | 1 |
| Ivy Zhang | 1 | 1 |
| Lisa Rarick | 1 | 1 |
| Tony O'Brien | 1 | 1 |
| Tony O'Brian | 1 | 1 |
| Justin File | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.